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Abstract: Collagen cross-linking (CXL) is a relatively new conservative approach for 
progressive corneal ectasia, which is able to strengthen corneal tissue reforming new covalent 
bonds. Subjective and objective results following this method seem to be promising. In recent 
years, newer CXL protocols have been developed to perform more effective and less invasive 
procedures. The increasing diffusion of CXL in the corneal ectatic disease has increased the 
need to have actual indices regarding the efficacy of the treatment. Evaluation of demarcation 
line (DL), a transition zone between the cross-linked anterior corneal stroma and the untreated 
posterior corneal stroma, is considered a measurement of the depth of CXL treatment into the 
stroma. Some evidence in the literature emphasize that DL could be a measure of effectiveness of 
the CXL. On the contrary, some authors believe that the “the deeper, the better” principle is rather 
a simplistic approach for interpreting the clinical importance of the corneal stromal DL.
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Introduction
Keratoconus is one of the leading causes of cornea transplant. Therapies based on the 
spectacles and contact lenses do not hinder the progression of the disease. Surgeries 
and corneal transplantation, though preserved as the first choice for the severe variants 
of the disease, have risks such as rejection of the transplanted cornea. Corneal cross-
linking (CXL) is a noble strategy based on the underlying pathology of the disease. The 
main indication for CXL is to slow the progression of corneal ectatic diseases, such as 
keratoconus, pellucid marginal degeneration (PMD), and keratoglobus.1,2 In addition 
to these primary forms, there also exist forms related to refractive surgery.3
Studies on keratoconus epidemiology reported an incidence of 1.3–22.3 cases per 
100,000 and a prevalence of 0.4–86 cases per 100,000.4 The incidence of keratectasia 
after laser in situ keratomileusis (LASIK) has been reported to be 0.04%–0.6%.5–7 
Keratoconus is a progressive noninflammatory disease of the cornea distinguished 
by para-central corneal thinning and ectasia, resulting in irregular astigmatism with 
impaired vision. In most cases, it is bilateral but often asymmetrical and it usually 
begins sometime in puberty and it progresses until the fourth decade, when the corneal 
shape generally becomes stable.8 The etiology of keratoconus is unknown including 
genetic, biochemical, and physical factors. There is no unique theory elucidating its 
range of clinical appearances, and it is probable that keratoconus is the manifestation 
for several different conditions. It usually appears as an isolated disease, but it has been 
associated with a number of ocular and systemic pathologies, including vernal disease, 
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retinitis pigmentosa, blue sclera, atopy, magnesium defi-
ciency, Down’s syndrome, Turner syndrome, and connective 
tissue disorders such as Marfan’s syndrome, Ehlers–Danlos 
syndrome, osteogenesis imperfecta, and pseudoxanthoma 
elasticum.9 Genetic factors have an incidence of up to 10%.10 
In keratoconus corneas, the protease enzymes are upregu-
lated while the activities of protease inhibitors are inhibited, 
involving an increasing digestion of stromal proteins with 
a consequent reduction in the biomechanical stability and 
corneal thinning.11,12 In diabetic patients, the severity of the 
pathology is inversely proportional.13 Corneal alterations in 
keratoconus involve changes in basement membrane struc-
ture, stromal collagen fiber, morphology of keratocytes, and 
abnormal cell–matrix interactions.14
Posterior keratoconus is a rare corneal anomaly, which 
is characterized by a total or localized noninflammatory 
thinning of the posterior stroma and a depression of the pos-
terior corneal surface, whereas the anterior surface remains 
more regular.15
Less common than keratoconus is PMD, which usually 
affects the para-central and the inferior peripheral cornea 
in ∼85% of cases, while the superior peripheral cornea in 
remaining 15%. It is a progressive noninflammatory disorder 
characterized by a band of thinning that usually involves the 
cornea between 4 o’clock and 8 o’clock positions, ie, 1 mm 
from the limbus. The etiology of PMD is not known. Corneal 
topography shows the typical “butterfly pattern” of an irregu-
lar astigmatism with a marked flattening along a vertical axis 
and a steepening of the inferior cornea.2,16
Corneal CXL
Corneal CXL with riboflavin and ultraviolet A (UV-A) is 
a technique to strengthen corneal tissue using riboflavin 
as a photosensitizer and UV-A to increase the formation of 
intra- and interfibrillar covalent bonds by photosensitized 
oxidation. This technique is able to flatten corneal steepening, 
stabilize the cornea, and reduce the refractive error improving 
the irregular astigmatism.17 Several studies confirm the effec-
tiveness and safety of conventional cross-linking procedure, 
which is also known as “Dresden protocol”,18–21 in which the 
interaction between 0.1% riboflavin molecules absorbed in 
corneal tissue and UV-A rays delivered at 3 mW/cm2 for 
30 minutes (5.4 J/cm2 energy dose) releases reactive oxygen 
species that promote the formation of “molecular bridges” 
between and within collagen fibers.17,22
Riboflavin (vitamin B2), because of its alkylisoalloxazine 
structure, allows the absorption of a wide range of light 
spectrum, including an absorption peak in UV-A range, so it 
is the standard photoinducer in cross-linking. An effective 
cross-linking requires a considerable corneal absorption of 
riboflavin; therefore, the epithelium debridement in standard 
protocols (epithelium-off [epi-off] CXL) has the goal of 
overcoming the barrier formed by corneal epithelium tight 
junctions that would limit the penetration of macromolecule 
as vitamin B2 (molecular weight: 376.37 g/mol).23 However, 
the epithelium debridement is not free from complications, 
where there is an increased risk of ulcers, infections, haze, 
scarring, infiltrates, longer recovery time, patient discom-
fort, and postoperative pain.24 Thus, some effort has been 
put into the development of transepithelial (epithelium-on, 
epi-on) CXL. Since riboflavin cannot penetrate intact cor-
neal epithelium due to its chemical properties, different 
strategies were studied to enhance transepithelial riboflavin 
penetration, such as increasing riboflavin imbibition time 
and new riboflavin solution formulations to facilitate its 
transepithelial penetration.
Therefore, some substances, such as benzalkonium chlo-
ride, ethylenediaminetetraacetic acid, and trometamol, were 
used to enhance the epithelial penetration of riboflavin with 
good results, allowing a transepithelial CXL. This technique 
was safe and effective especially in ultrathin keratoconic 
corneas (pachymetry ,400 µm), to avoid CXL cytotoxic 
effect on endothelium, crystalline lens, and other intraocular 
tissue.25 In fact, in transepithelial CXL, the epithelium acts 
as a UV filter because of the high absorption coefficient; in 
the absence of a photosensitizer, UV-A light at wavelengths 
of 350 nm and irradiance of 3 mW/cm2 would not cause 
significant cytotoxicity. The addition of riboflavin reduces 
the damage threshold compared with UV-A light alone and 
produces oxygen-free radicals inducing CXL.
In recent years, to perform less invasive procedures, atten-
tion has focused on the possibility to create new protocols 
to minimize UV exposure duration, reduce postoperative 
discomfort, and further decrease the complication rate.3 In 
this direction, the accelerated, high-fluence CXL arises, based 
on the principle of photochemical reciprocity, known as the 
law of Bunsen–Roscoe, which states that in a system the 
same photochemical effect can be achieved through reduced 
irradiation interval while maintaining a constant total energy 
level by an increase in irradiation intensity.26,27
Ocular iontophoresis is a noninvasive protocol that uses 
the ions flow in an electric field to apply the negatively 
charged riboflavin within the stroma through the corneal 
epithelial barrier. In the most recent CXL protocols, it is a 
well-known method investigated to enhance the penetration 
of photosensitizer in the stroma. It has been evidenced that 
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by using iontophoresis, a 5-minute imbibition achieves a suf-
ficient riboflavin concentration in the corneal stroma for CXL 
treatment, preserving epithelial integrity.28 Several ex vivo 
studies confirmed the effectiveness of iontophoresis imbibi-
tion in obtaining an adequate riboflavin concentration into the 
stroma and the induction of evident biomolecular and struc-
tural changes of the treated corneas.29 To reduce the admin-
istration time, UV-A irradiation protocols that are different 
from the standard technique (3 mW/cm2 for 30 minutes) can 
be used. Literature shows, in ex vivo experiments, a similar 
increase in corneal biomechanical stiffness using 10 mW/cm2 
illumination intensity for 9 minutes and the standard protocol 
(3 mW/cm2 for 30 minutes).30 Preliminary clinical results of 
iontophoresis-assisted transepithelial (I-CXL) are very prom-
ising, reducing or blocking the progression of keratoconus 
without significant complications.31,32
CXL combined with other 
treatments
Corneal cross-linking has been used in combination with 
other treatments in keratoconic eyes and post-laser ectasia 
to optimize visual outcomes. Combined CXL and limited 
topography-guided photorefractive keratectomy in selected 
eyes with moderate ectasia and adequate corneal thicknesses 
have been evidenced to be effective with improvements in 
visual, refractive, and topographic data and stabilization of 
the ectatic disease in many eyes.33–35 Such different treat-
ment modalities have been reported to be associated with 
significant improvements in the quality of life. However, 
the follow-up in these studies is limited to 1–3 years so that 
the long-term results are not known. In addition, significant 
corneal haze/scarring has been reported.36 CXL has also been 
combined with intracorneal ring segment insertion, suggesting 
a potential additional effect of CXL.37,38 The transepithelial 
iontophoresis CXL has also been used in the treatment of 
PMD associated with sliding keratoplasty, proving to be safe 
and effective in the treatment of advanced PMD.39
CXL has also been associated with refractive procedures 
such as photorefractive keratectomy and LASIK to improve 
the long-term stability and to reduce the possible occurrence 
of postoperative ectasia. Up to now, such studies are very 
limited in terms of eyes treated, efficacy, and long-term 
follow-up, although a study in CXL after hyperopic LASIK 
demonstrated less regression of refractive effects over the 
follow-up period.40
Demarcation line
After corneal CXL in keratoconic eyes, some confocal 
microscopic studies evidenced edema, rarefaction of kera-
tocytes in the anterior and mid-stroma, nerve loss, and focal 
endothelial changes in the immediate postoperative period 
(Table 1).41–43 Ultrastructural study shows that changes in 
stromal keratocytes with cell and collagen fiber shrinkage, 
chromatin condensation, and apoptotic bodies are detectable 
within 60 minutes after UV-A–riboflavin treatment.44 In the 
excited state, post UV-A exposure, riboflavin can produce 
radicals or singlet oxygen molecules that induce covalent 
bonds that can connect one polymer chain to another, caus-
ing in vivo cornea links in collagen fibers.45 Photochemically 
induced cross-links in cornea can be detected through struc-
tural changes secondary to CXL. Ex vivo studies evidence 
an increased resistance to enzymatic degradation processes 
involved in progressive thinning of the cornea in keratoconus. 
Corneas that underwent CXL treatment present an inferior 
rate of enzymatic collagenasic degradation when compared 
with an untreated cornea. Corneal CXL acts unevenly within 
the corneal thickness; UV-A intensity is inversely propor-
tional to deepening in stromal tissue for several reasons; 
Table 1 Comparative findings of corneal stromal DL depth after CXL
Study Patients (N) CXL protocol DL depth Detection modality Time of DL 
detection
Seiler and Hafezi47 16 Conventional 300 µm Confocal microscopy 2 weeks
Doors et al51 28 Conventional 313 µm AS-OCT 1 month
Yam et al49 40 Conventional 281 µm AS-OCT 6 months
Filippello et al61 20 Transepithelial 100 µm AS-OCT 2 weeks
Kymionis et al56 16 Conventional vs accelerated 351 µm; 288 µm AS-OCT 1 month
Mazzotta et al59 20 Accelerated PL vs CL 215 µm PL; 160 µm CL AS-OCT/confocal 
microscopy
1 month
Moramarco et al50 60 Accelerated PL vs CL 213 µm PL; 149 µm CL AS-OCT 1 month
Bonnel et al64 12 iontophoresis 247 µm AS-OCT 1 month
Kymionis et al48 29 Conventional vs accelerated 342 µm; 313 µm AS-OCT 1 month
Bikbova and Bikbov65 119 Conventional vs iontophoresis 292 µm; 172 µm AS-OCT 2 weeks
Abbreviations: AS-OCT, anterior segment optical coherence tomography; CL, continuous light; CXL, collagen cross-linking; DL, demarcation line; PL, pulsed light.
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and primarily riboflavin concentration decreases linearly 
with increasing of corneal depth, in accordance with diffu-
sion gradient. Furthermore, according to Lambert–Beer law, 
65% of UV radiation is absorbed in the first 200 µm. The 
consequence of a higher UV intensity in anterior cornea is a 
greater stiffening effect within first 250 µm.28
Corneal cross-linking causes a dose-dependent kerato-
cytes damage. Wollensak et al46 described cellular apoptosis 
to a depth of 300 µm radiating with UV-A at 3 mW/cm2. 
Histopathological studies showed an already complete 
keratocyte apoptosis limited to the anterior stroma within 
24 hours.46 An increased density of the extracellular matrix 
was evidenced to a depth of 300–350 µm. By using the 
slit-lamp examination, this appears as a “demarcation line” 
(DL), a transition zone between the cross-linked stroma 
and untreated tissue, which can be seen as early as 2 weeks 
(Figure 1). It is an area of hyper-reflectivity due to different 
refractive indices or reflective properties of cross-linked vs 
untreated corneal stroma. Some authors characterized the 
corneal stromal DL as a clinical sign to evaluate the depth 
of the CXL treatment.47,48
Some studies hypothesize the role of the DL after CXL 
depth as representative of CXL effectiveness.49–51 Recently, 
the essential debate focused on whether the depth of the 
corneal stromal DL is indeed a true indicator of CXL effi-
cacy. The main question is whether “the deeper, the better” 
principle can be applied to CXL. Actually, other confounding 
factors may interfere with the clinical interpretation of the 
depth of corneal DL after CXL. Therefore, some authors 
believe that the “the deeper, the better” principle is rather a 
simplistic approach for interpreting the clinical importance 
of the corneal stromal DL.52
In recent years, anterior segment optical coherence 
tomography (AS-OCT) and confocal microscopy have been 
used as tools to assess the depth of DL and consequently the 
depth of the cross-linking effect (Figure 2). Kymionis et al53 
compared the depth of stromal DL using both AS-OCT and 
confocal microscopy studying the transition area between 
the cellular and acellular zone, thereby showing no statistical 
significant differences between the two measurements.
By using the AS-OCT, the stromal DL is detected within 
an enhanced image of the cornea in the horizontal meridian. 
The image is captured when the corneal reflex is visible, and 
the depth of DL is measured using the caliper tool provided 
by the manufacturer.
Doors et al described the best visibility of corneal stromal 
DL using AS-OCT at 1 month after CXL treatment, with an 
average DL depth of 313 µm; Yam et al measured the depth 
of DL at 6 months highlighting that the severity of ectasia 
and age may cause a worse DL visibility.49,51
A characteristic DL depth pattern, deeper centrally than 
peripherally has been observed in different studies; this is 
probably due to the top-hat beam profile of UV-A optical 
system that does not compensate for natural corneal curva-
ture, so the UV-A beam enters the cornea at a non-orthogonal 
angle in the corneal periphery (Figure 2).54 
DL in accelerated epi-off CXL
Corneal stromal DL after CXL using both the standard 
Dresden protocol (30 minutes with 3 mW/cm2) and a modi-
fied accelerated protocol (14 minutes with 9 mW/cm2) was 
evaluated according to the photochemical law of reciprocity 
(Bunsen–Roscoe law). There was no statistically significant 
'/
Figure 1 Biomicroscopic image of keratoconus eye at slit lamp 6 months after 
epi-off standard corneal CXL.
Note: DL is visible in the middle of the cornea.
Abbreviations: CXL, collagen cross-linking; DL, demarcation line; epi-off, 
epithelium-off.
P P P

Figure 2 AS-OCT of keratoconus eye 6 months after epi-off corneal cross-linking 
radiating with Uv-A at 3 mw/cm2.
Note: DL is visible to a depth of 314 µm.
Abbreviations: AS-OCT, anterior segment optical coherence tomography; DL, 
demarcation line; epi-off, epithelium-off; Uv-A, ultraviolet A.
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difference in corneal stromal DL depth between the two 
groups, with a mean depth of 337 µm in the first group and 
322 µm in the second group.55 However, Kymionis et al 
evaluated the corneal stromal DL depth after very high-
intensity (18 mW/cm2) UV-A irradiation for a 5-minute 
collagen CXL. Despite the easy identification of DL using 
AS-OCT, it seemed to be shallower when compared with 
the previously described 10-minute protocol and standard 
Dresden protocol (Figure 3).48,56 
This confirms Shetty et al’s57 findings comparing the clini-
cal effect and DL using four different protocols; they have 
noticed the presence of a DL at a depth of 280±47 mm in 
3 mW/cm2 irradiation for the 30-minute group, 292±73 µm in 
9 mW/cm2 for the 10-minute group, 203±36 µm in 18 mW/cm2 
for the 5-minute group, and 201±82 µm in 30 mW/cm2 for the 
3-minute group. A deeper and well-defined DL was found in 
the 3 mW/cm2 and 9 mW/cm2 groups. However, a patchy and 
an incomplete DL was noted in the higher intensity groups.
Bunsen–Roscoe law may be valid for the certain dose 
range, meaning that corneal cross-linking effect may depend 
on a threshold that the increase in the illumination intensity is 
limited up to 40–45 mW and the decrease in the illumination 
time is limited from 30 minutes to 2 minutes.
However, no statistically significant increase can be 
achieved for higher intensities ranging from 50 mW to 
90 mW (illumination times of ,2 minutes) probably due to 
complex biochemistry that is not completely understood until 
now. As the anterior stroma is more important in terms of 
biomechanical stability of the cornea, despite a significantly 
less DL depths after accelerated CXL, the cross-linking 
effect may also be strong enough to stop the progression of 
corneal ectasia which however must be validated by future 
long-term clinical studies.58
Kymionis et al56 suggested that Bunsen–Roscoe law of 
reciprocity may not directly apply to CXL in living corneal 
tissue; thus, an increased total energy dose should probably 
be applied to the keratoconic cornea to achieve a treatment 
effect comparable with the already proven effective standard 
Dresden CXL protocol.
A study using confocal microscopy and AS-OCT after 
epi-off pulsed light (1 second on/1 second off) accelerated 
collagen cross-linking (PL-ACXL) and epi-off continuous 
light accelerated collagen cross-linking (CL-ACXL) evi-
denced a deeper DL in the PL-ACXL group. This could be 
probably due to an additional oxygen re-diffusion during 
pauses allowing more singlet oxygen release for the cross-
linking of collagen molecules.59 Moramarco et al50 showed 
a mean depth of DL of 149 µm in the CL-ACXL group and 
213 µm in the PL-ACXL group noting the importance of 
performing AS-OCT no later than 1 month after CXL to 
obtain the most accurate measure of the depth of DL.
Oxygen is essential for the photochemical polymeriza-
tion reaction in CXL and is probably the limiting factor; it 
is theoretically possible that increasing fluence in an attempt 
to accelerate photopolymerization will not allow sufficient 
time for oxygen to diffuse and participate in the reaction, 
limiting the procedure.60
DL in transepithelial epi-on CXL
Transepithelial CXL with substances such as benzalkonium 
chloride, ethylenediaminetetraacetic acid, and trometamol to 
enhance the epithelial permeability of riboflavin has been 
developed as an alternative technique for thin corneas.25 In 
epi-on CXL, OCT analysis after 2 weeks of CXL treatment 
shows a dense area in the corneal stroma (not present before 
CXL) that was linear in shape and positioned ∼100 µm from 
the corneal epithelial layer, slightly beneath Bowman’s mem-
brane (Figure 4). These observations appear to highlight the 
possible role of the epithelium (also containing riboflavin) in 
shielding UV light.61 It is unclear whether the shallower DL 
using the epi-on approach is due to the limited penetration of 
riboflavin into the stroma, or it is a result of reduced UV-A 
light penetration by shielding from riboflavin-impregnated 
intact corneal epithelium.62
Bottos et al63 recognized the cause of different corneal 
stromal DL depth in decreased penetration of riboflavin 
into the stroma rather than the result of reduced UV-A 
light penetration through epithelium barrier. Furthermore, 
biomechanical effects of corneal CXL are closely related to 
oxygen supply, and the intact epithelium acts as a barrier to 
rapid oxygen diffusion into the corneal stroma and results 
P P P

Figure 3 AS-OCT of keratoconus eye 6 months after accelerated epi-off corneal 
cross-linking radiating with Uv-A at 10 mw/cm2.
Note: DL is visible to a depth of 290 µm.
Abbreviations: AS-OCT, anterior segment optical coherence tomography; DL, 
demarcation line; epi-off, epithelium-off; Uv-A, ultraviolet A.
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in suboptimal cross-linking. These findings underscore, at a 
clinical level, the importance of corneal tissue oxygenation 
for effective CXL, as suggested by Richoz et al.60
DL in transepithelial epi-on 
iontophoresis CXL
I-CXL, when compared with transepithelial CXL, increases 
the penetration of riboflavin through intact epithelium 
enhancing the stromal amount of riboflavin while report-
ing lower photosensitizer amounts rather than standard 
epi-off protocols.32
I-CXL creates a DL that can be visualized with AS-OCT, 
which seems less easily distinguishable and shallower than 
in conventional CXL, with a particular OCT appearance 
(Figure 5). However, its depth and visualization seem to 
be more similar to conventional CXL than transepithelial 
CXL.64 Confocal microscopy noted loss of keratocytes 
in the anterior and intermediate corneal stroma. DL was 
detected, ∼150–210 µm, in the I-CXL group with a char-
acteristic pattern of “honeycomb” structure, which was less 
homogeneous compared with standard CXL. Bikbova and 
Bikbov65 evidenced that a DL was not clearly measurable 
over time in patients who underwent I-CXL. They showed 
that a DL was observed in only 45% patients 1 month after 
transepithelial I-CXL and was completely absent in all 
these patients for 3 months post CXL. Vinciguerra et al32 
described that, as in I-CXL, it is possible to detect an 
increase in reflectance in AS-OCT scans; however, no DL 
was visible and this finding could be explained by either the 
different concentration gradient induced by iontophoresis or 
a reduced CXL effect. Zhang et al66 showed that the epithe-
lial cells are not enriched with riboflavin. For this reason, 
only a small part of the UV light should be absorbed by the 
epithelium (∼15%–20%).
Conclusion
Corneal cross-link is a strategy based on the underlying 
pathology of the corneal ectatic diseases. After corneal CXL 
procedures, a stromal DL can be observed within the corneal 
stroma at 1 month postoperatively. It would be unreasonable 
to disagree with the interpretation of the depth of DL as an 
indirect measurement of CXL penetration within the stroma, 
but the current knowledge suggests that the “the deeper, the 
better” principle is rather a simplistic approach for interpret-
ing the clinical importance of the corneal stromal DL.
We can conclude that there is still much to understand 
about the changes of corneal structure after the photochemical 
CXL reaction. Experimental and clinical researchers on CXL 
have proven a good effectiveness in stabilizing keratoconus 
and iatrogenic keratectasia. Moreover, the constant aim of 
basic and clinical research will be the identification of the 
best strategies of treatment that is able to obtain the best 
clinical efficacy together with the maximum safety profile 
with very few side effects.
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Figure 4 AS-OCT of keratoconus eye 6 months after epi-on corneal cross-linking 
radiating with Uv-A at 3 mw/cm2.
Note: DL is fairly visible to a depth of 180 µm.
Abbreviations: AS-OCT, anterior segment optical coherence tomography; DL, 
demarcation line; epi-on, epithelium-on; Uv-A, ultraviolet A.
P PP P

Figure 5 AS-OCT of keratoconus eye 6 months after epi-on corneal cross-linking 
with iontophoresis imbibition radiating with Uv-A at 10 mw/cm2.
Note: DL is barely discernible to a depth of 280 µm.
Abbreviations: AS-OCT, anterior segment optical coherence tomography; DL, 
demarcation line; epi-on, epithelium-on; Uv-A, ultraviolet A.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
10
0.
14
2.
85
 o
n 
15
-N
ov
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1809
Corneal stromal demarcation line after CXL
 4. Gordon-Shaag A, Millodot M, Shneor E, Liu Y. The genetic and environ-
mental factors for keratoconus. Biomed Res Int. 2015;2015:795738.
 5. Binder PS. Analysis of ectasia after laser in situ keratomileusis: risk 
factors. J Cataract Refract Surg. 2007;33(9):1530–1538.
 6. Spadea L, Cantera E, Cortes M, Conocchia NE, Stewart CW. Corneal 
ectasia after myopic laser in situ keratomileusis: a long-term study. Clin 
Ophthalmol. 2012;6:1801–1813.
 7. Kirwan C, O’Malley D, O’Keefe M. Corneal hysteresis and corneal 
resistance factor in keratoectasia: finding using the Reichert ocular 
response analyzer. Ophthalmologica. 2008;222(5):334–337.
 8. Vazirani J, Basu S. Keratoconus: current perspectives. Clin Ophthalmol. 
2013;7:2019–2030.
 9. O’Brart DP. Corneal collagen cross-linking: a review. J Optom. 2014; 
7(3):113–124.
 10. Hammerstein W. Zur genetic des keratoconus [The genetics of 
keratoconus]. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 
1974;190(4):293–308.
 11. Zhou L, Sawaguchi S, Twining SS, Sugar J, Feder RS, Yue BY. Expres-
sion of degradative enzymes and protease inhibitors in corneas with 
keratoconus. Invest Ophthalmol Vis Sci. 1998;39(7):1117–1124.
 12. Andreassen T, Simonsen AH, Oxlund H. Biomechanical properties of 
keratoconus and normal corneas. Exp Eye Res. 1980;31(4):435–441.
 13. Kuo IC, Broman A, Pirouzmanesh A, Melia M. Is there an associa-
tion between diabetes and keratoconus. Ophthalmology. 2006;113(2): 
184–190.
 14. Cannon DJ, Foster CS. Collagen crosslinking in keratoconus. Invest 
Ophthalmol Vis Sci. 1978;17(1):63–65.
 15. Spadea L, Maraone G, Cagini C. A case of unilateral circumscribed 
posterior keratoconus evaluated by three different imaging tools: optical 
coherence tomography, videokeratography, and Scheimpflug corneal 
tomography. Int Ophthalmol. 1–5. Epub May 13, 2016.
 16. Panos GD, Hafezi F, Gatzioufas Z. Pellucid marginal degeneration and 
keratoconus; differential diagnosis by corneal topography. J Cataract 
Refract Surg. 2013;39(6):968.
 17. Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. 
Exp Eye Res. 1998;66(1):97–103.
 18. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking 
with riboflavin and ultraviolet-A light in keratoconus: long-term results. 
J Cataract Refract Surg. 2008;34(5):796–801.
 19. Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term results 
of riboflavin ultraviolet A corneal collagen crosslinking for kerato-
conus in Italy: the Siena eye cross study. Am J Ophthalmol. 2010; 
149(4):585–593.
 20. Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, 
Snibson GR. A randomized controlled trial of corneal collagen cross-
linking in progressive keratoconus: preliminary results. J Refract Surg. 
2008;24(7):S720–S725.
 21. Caporossi A, Mazzotta C, Baiocchi S, Caporossi T, Denaro R. Age-
related long-term functional results after riboflavin UV A corneal 
crosslinking. J Ophthalmol. 2011;2011:608041.
 22. Spoerl E, Seiler T. Techniques for stiffening the cornea. J Refract Surg. 
1999;15(6):711–713.
 23. Randleman JB, Khandelwal SS, Hafezi F. Corneal cross-linking. Surv 
Ophthalmol. 2015;60(6):509–523.
 24. Spadea L, Salvatore S, Paroli MP, Vingolo EM. Recovery of corneal sensi-
tivity after collagen crosslinking with and without epithelial debridement in 
eyes with keratoconus. J Cataract Refract Surg. 2015;41(3):527–532.
 25. Spadea L, Mencucci R. Transepithelial corneal collagen cross-linking in 
ultrathin keratoconic corneas. Clin Ophthalmol. 2012;6:1785–1792.
 26. Gatzioufas Z, Richoz O, Brugnoli E, Hafezi F. Safety profile of high-fluence 
corneal collagen cross-linking for progressive keratoconus: preliminary results 
from a prospective cohort study. J Refract Surg. 2013;29(2):846–848.
 27. Beshtawi IM, Akhtar R, Hillarby MC, et al. Biomechanical changes 
after repeated collagen cross-linking on human corneas assessed in vitro 
using scanning acoustic microscopy. Invest Ophthalmol Vis Sci. 2014; 
55(3):1549–1554.
 28. Raiskup F, Spoerl E. Corneal crosslinking with riboflavin and ultraviolet 
A. I. Principles. Ocul Surf. 2013;11(2):65–74.
 29. Mastropasqua L, Lanzini M, Curcio C, et al. Structural modifications 
and tissue response after standard epi-off and iontophoretic corneal 
crosslinking with different irradiation procedures. Invest Ophthalmol 
Vis Sci. 2014;55(4):2526–2533.
 30. Mencucci R, Ambrosini S, Paladini I, et al. Early effects of corneal 
collagen cross-linking by iontophoresis in ex vivo human corneas. 
Graefes Arch Clin Exp Ophthalmol. 2015;253(2):277–286.
 31. Bikbova G, Bikbov M. Transepithelial corneal collagen cross-linking 
by iontophoresis of riboflavin. Acta Ophthalmol. 2014;92(1):30–34.
 32. Vinciguerra P, Randleman JB, Romano V, et al. Transepithelial ion-
tophoresis corneal collagen cross-linking for progressive keratoconus: 
initial clinical outcomes. J Refract Surg. 2014;30(11):746–753.
 33. Kanellopoulos AJ, Binder PS. Management of corneal ectasia after 
LASIK with combined, same-day, topography-guided partial transepi-
thelial PRK and collagen cross-linking: the Athens protocol. J Refract 
Surg. 2011;27(5):323–331.
 34. Kymionis GD, Portaliou DM, Diakonis VF, et al. Management of 
post laser in situ keratomileusis ectasia with simultaneous topography 
guided photorefractive keratectomy and collagen cross-linking. Open 
Ophthalmol J. 2011;5:11–13.
 35. Spadea L, Paroli M. Simultaneous topography-guided PRK followed 
by corneal collagen cross-linking after lamellar keratoplasty for kera-
toconus. Clin Ophthalmol. 2012;6:1793–1800.
 36. Kymionis GD, Portaliou DM, Diakonis VF, et al. Posterior linear stromal 
haze formation after simultaneous photorefractive keratectomy followed 
by corneal collagen cross-linking. Invest Ophthalmol Vis Sci. 2010; 
51(10):5030–5033.
 37. Ertan A, Karacal H, Kamburoglu G. Refractive and topographic results 
of transepithelial cross-linking treatment in eyes with intacs. Cornea. 
2009;28(7):719–723.
 38. Renesto Ada C, Melo LA Jr, Sartori Mde F, Campos M. Sequential 
topical riboflavin with or without ultraviolet a radiation with delayed 
intracorneal ring segment insertion for keratoconus. Am J Ophthalmol. 
2012;153(5):982–993.
 39. Spadea L, Maraone G, Cagini C. Sliding keratoplasty followed by tran-
sepithelial iontophoresis collagen cross-linking for pellucid marginal 
degeneration. J Refract Surg. 2016;32(1):47–50.
 40. Kanellopoulos AJ. Long-term safety and efficacy follow-up of prophy-
lactic higher fluence collagen cross-linking in high myopic laser-assisted 
in situ keratomileusis. Clin Ophthalmol. 2012;6:1125–1130.
 41. Croxatto JO, Tytiun AE, Argento CJ. Sequential in vivo confo-
cal microscopy study of corneal wound healing after cross-
linking in patients with keratoconus. J Refract Surg. 2010;26(9): 
638–645.
 42. Mazzotta C, Balestrazzi A, Traversi C, et al. Treatment of progres-
sive keratoconus by riboflavin UVA induced cross linking of corneal 
collagen: ultrastructural analysis by Heidelberg retinal tomography 
II in vivo confocal microscopy in humans. Cornea. 2007;26(4): 
390–397.
 43. Mazzotta C, Balestrazzi A, Baiocchi S, Traversi C, Caporossi A. Stromal 
haze after combined riboflavin-UVA corneal collagen cross-linking in 
keratoconus: in vivo confocal microscopic evaluation. Clin Experiment 
Ophthalmol. 2007;35(6):580–582.
 44. Dhaliwal JS, Kaufman SC. Corneal collagen cross-linking: a confocal, 
electron, and light microscopy study of eye bank corneas. Cornea. 2009; 
28(1):62–67.
 45. Kamaev P, Friedman MD, Sherr E, Muller D. Photochemical kinetics 
of corneal cross-linking with riboflavin. Invest Ophthalmol Vis Sci. 
2012;53(4):2360–2367.
 46. Wollensak G, Spoerl E, Wilsch M, Seiler T. Keratocyte apoptosis after 
corneal collagen cross-linking using riboflavin/UVA treatment. Cornea. 
2004;23(1):43–49.
 47. Seiler T, Hafezi F. Corneal cross-linking-induced stromal demarcation 
line. Cornea. 2006;25(9):1057–1059.
 48. Kymionis GD, Tsoulnaras KI, Liakopoulos DA, Skatharoudi CA, 
Grentzelos MA, Tsakalis NG. Corneal stromal demarcation line depth 
following standard and a modified high intensity corneal cross-linking 
protocol. J Refract Surg. 2016;32(4):218–222.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
10
0.
14
2.
85
 o
n 
15
-N
ov
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1810
Spadea et al
 49. Yam JC, Chan CW, Cheng AC. Corneal collagen cross-linking demar-
cation line depth assessed by Visante OCT after CXL for keratoconus 
and corneal ectasia. J Refract Surg. 2012;28(7):475–481.
 50. Moramarco A, Iovieno A, Sartori A, Fontana L. Corneal stromal 
demarcation line after accelerated crosslinking using continuous and 
pulsed light. J Cataract Refract Surg. 2015;41(11):2546–2551.
 51. Doors M, Tahzib NG, Eggink FA, Berendschot TT, Webers CA, 
Nuijts RM. Use of anterior segment optical coherence tomography to 
study corneal changes after collagen cross-linking. Am J Ophthalmol. 
2009;148(6):844–851.
 52. Gatzioufas Z, Balidis M, Kozeis N. Is the corneal stromal demarca-
tion line depth a true indicator of corneal collagen crosslinking effi-
cacy? J Cataract Refract Surg. 2016;42(5):804.
 53. Kymionis GD, Grentzelos MA, Plaka AD, et al. Correlation of the cor-
neal collagen cross-linking demarcation line using confocal microscopy 
and anterior segment optical coherence tomography in keratoconic 
patients. Am J Ophthalmol. 2014;157(1):110–115.
 54. Malta JB, Renesto AC, Moscovici BK, Soong HK, Campos M. Stromal 
demarcation line induced by corneal cross-linking in eyes with kera-
toconus and non keratoconic asymmetric topography. Cornea. 2015; 
34(2):199–203.
 55. Kymionis GD, Tsoulnaras KI, Grentzelos MA, et al. Evaluation of cor-
neal stromal demarcation line depth following standard and a modified-
accelerated collagen cross-linking protocol. Am J Ophthalmol. 2014; 
158(4):671–675.
 56. Kymionis GD, Tsoulnaras KI, Grentzelos MA, et al. Corneal stroma 
demarcation line after standard and high-intensity collagen crosslink-
ing determined with anterior segment optical coherence tomography. 
J Cataract Refract Surg. 2014;40(5):736–740.
 57. Shetty R, Pahuja NK, Nuijts RM, et al. Current protocols of corneal 
collagen crosslinking – visual, refractive and tomographic outcomes. 
Am J Ophthalmol. 2015;160(2):243–249.
 58. Ozgurhan EB, Sezgin Akcay BI, Yildirim Y, Karatas G, Kurt T, 
Demirok A. Evaluation of corneal stromal demarcation line after 
two different protocols of accelerated corneal collagen cross-linking 
procedures using anterior segment optical coherence tomography and 
confocal microscopy. J Ophthalmol. 2014;2014:981893.
 59. Mazzotta C, Traversi C, Caragiuli S, Rechichi M. Pulsed vs continuous 
light accelerated corneal collagen crosslinking: in vivo qualitative inves-
tigation by confocal microscopy and corneal OCT. Eye (Lond). 2014; 
28(10):1179–1183.
 60. Richoz O, Hammer A, Tabibian D, Gatzioufas Z, Hafezi F. The biome-
chanical effect of corneal collagen cross-linking (CXL) with riboflavin 
and UV-A is oxygen dependent. Transl Vis Sci Technol. 2013;2(7):6.
 61. Filippello M, Stagni E, O’Brart D. Transepithelial corneal collagen 
crosslinking: bilateral study. J Cataract Refract Surg. 2012;38(2): 
283–291.
 62. Chen X, Stojanovic A, Eidet JR, Utheim TP. Corneal collagen cross-
linking (CXL) in thin corneas. Eye Vis (Lond). 2015;2:15.
 63. Bottos KM, Schor P, Dreyfuss JL, Nader HB, Chamon W. Effect of 
corneal epithelium on ultraviolet-A and riboflavin absorption. Arq Bras 
Oftalmol. 2011;74(5):348–351.
 64. Bonnel S, Berguiga M, De Rivoyre B, et al. Demarcation line evaluation 
of iontophoresis-assisted transepithelial corneal collagen cross-linking 
for keratoconus. J Refract Surg. 2015;31(1):36–40.
 65. Bikbova G, Bikbov M. Standard corneal collagen crosslinking versus tran-
sepithelial iontophoresis-assisted corneal crosslinking, 24 months follow-up: 
randomized control trial. Acta Ophthalmol. Epub 2016 Apr 4.
 66. Zhang Y, Sukthankar P, Tomich JM, Conrad GW. Effect of the synthetic 
NC-1059 peptide on diffusion of riboflavin across an intact corneal 
epithelium. Invest Ophthalmol Vis Sci. 2012;53(6):2620–2629.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
10
0.
14
2.
85
 o
n 
15
-N
ov
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
